J. Goldman & Co’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
Other funds holding TRDA
BBA
J. Goldman & Co's TRDA Position: Q3 2026 in Review
J. Goldman & Co opened a new position in Entrada Therapeutics (TRDA) in Q3 2026: 268,081 shares worth $1.7M. The stake represents 0.03% of the portfolio and ranks #428 among its holdings.
132 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.
- J. Goldman & Co held 268,081 shares of Entrada Therapeutics worth $1.7M as of Q3 2026.
- Entrada Therapeutics was a new J. Goldman & Co position in Q3 2026.
- Entrada Therapeutics made up 0.03% of J. Goldman & Co's portfolio in Q3 2026, its #428 holding.
- 132 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.
Based on J. Goldman & Co's 13F filing for Q3 2026, filed 16 Nov 2026.